Lilly, Scribe team up for neuro diseases CRISPR therapies

room mom

Scribe Therapeutics is partnering with the Eli Lilly unit (New York Stock Exchange: LLYTherapeutics prevail and grant rights to CRISPR X-Editing (XE) technologies to develop in vivo treatments for neuromuscular diseases.

Under the agreement, Scribe of Alameda, California, will receive $75 million consisting of an upfront payment

CRISPRdiseasesLillyneuroScribeTeamtherapies
Comments (0)
Add Comment